Zomedica Capital Surpluse vs Net Receivables Analysis

ZOM Stock

USD 0.14 0.01 7.69%

Zomedica Pharmaceuticals financial indicator trend analysis is more than just analyzing Zomedica Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Zomedica Pharmaceuticals is a good investment. Please check the relationship between Zomedica Pharmaceuticals Capital Surpluse and its Net Receivables accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

Capital Surpluse vs Net Receivables

Capital Surpluse vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Zomedica Pharmaceuticals Capital Surpluse account and Net Receivables. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Zomedica Pharmaceuticals' Capital Surpluse and Net Receivables is 0.96. Overlapping area represents the amount of variation of Capital Surpluse that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Zomedica Pharmaceuticals Corp, assuming nothing else is changed. The correlation between historical values of Zomedica Pharmaceuticals' Capital Surpluse and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Surpluse of Zomedica Pharmaceuticals Corp are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Capital Surpluse i.e., Zomedica Pharmaceuticals' Capital Surpluse and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Capital Surpluse

Net Receivables

Most indicators from Zomedica Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Zomedica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

At this time, Zomedica Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 30th of April 2024, Sales General And Administrative To Revenue is likely to grow to 1.30, while Issuance Of Capital Stock is likely to drop 0.00.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.5M	6.7M	6.3M	6.6M
Interest Income	321.1K	2.5M	5.6M	5.9M

Depreciation And Amortization Interest Income

Zomedica Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Other Stockholder Equity	Total Liab	Total Current Assets	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Common Stock	Net Tangible Assets	Property Plant And Equipment Net	Accounts Payable	Non Current Liabilities Total	Property Plant And Equipment Gross	Short Long Term Debt	Short Term Debt	Intangible Assets
Total Assets		-0.09	0.92	1.0	-0.55	-0.95	0.56	0.95	0.39	0.2	0.93	0.76	0.84	0.94	0.91	0.99	0.77	-0.13	0.99	0.76	0.89	0.51	0.77	0.82	0.84	0.95
Other Current Liab	-0.09		0.0	-0.1	-0.13	-0.01	0.13	-0.16	0.54	0.92	0.0	0.02	0.15	0.0	-0.15	-0.03	0.27	0.17	-0.09	-0.15	0.0	0.25	-0.18	-0.06	0.02	-0.17
Total Current Liabilities	0.92	0.0		0.91	-0.23	-0.97	0.25	0.97	0.37	0.33	0.73	0.88	0.84	0.76	0.98	0.94	0.8	-0.11	0.91	0.91	1.0	0.42	0.92	0.83	0.88	0.96
Total Stockholder Equity	1.0	-0.1	0.91		-0.55	-0.94	0.56	0.95	0.38	0.18	0.93	0.76	0.83	0.94	0.91	0.99	0.77	-0.13	0.99	0.75	0.89	0.49	0.76	0.81	0.83	0.95
Net Debt	-0.55	-0.13	-0.23	-0.55		0.41	-1.0	-0.25	-0.21	-0.14	-0.81	-0.05	-0.45	-0.79	-0.16	-0.52	-0.32	0.08	-0.55	0.01	-0.17	-0.53	0.0	-0.45	-0.32	-0.31
Retained Earnings	-0.95	-0.01	-0.97	-0.94	0.41		-0.42	-0.94	-0.34	-0.32	-0.83	-0.81	-0.91	-0.85	-0.93	-0.97	-0.79	0.12	-0.95	-0.86	-0.96	-0.56	-0.86	-0.91	-0.91	-0.94
Cash	0.56	0.13	0.25	0.56	-1.0	-0.42		0.26	0.21	0.14	0.82	0.06	0.46	0.8	0.17	0.53	0.33	-0.08	0.56	0.01	0.19	0.54	0.01	0.47	0.34	0.32
Non Current Assets Total	0.95	-0.16	0.97	0.95	-0.25	-0.94	0.26		0.36	0.16	0.76	0.86	0.79	0.78	0.99	0.95	0.76	-0.12	0.94	0.88	0.97	0.36	0.89	0.76	0.84	0.99
Non Currrent Assets Other	0.39	0.54	0.37	0.38	-0.21	-0.34	0.21	0.36		0.68	0.36	0.43	0.45	0.37	0.37	0.4	0.25	0.09	0.44	0.36	0.35	0.38	0.34	0.05	0.47	0.38
Other Assets	0.2	0.92	0.33	0.18	-0.14	-0.32	0.14	0.16	0.68		0.21	0.34	0.45	0.21	0.18	0.27	0.45	0.13	0.21	0.19	0.32	0.43	0.16	0.21	0.36	0.15
Cash And Short Term Investments	0.93	0.0	0.73	0.93	-0.81	-0.83	0.82	0.76	0.36	0.21		0.54	0.79	1.0	0.69	0.91	0.68	-0.13	0.92	0.51	0.69	0.61	0.52	0.77	0.73	0.78
Other Stockholder Equity	0.76	0.02	0.88	0.76	-0.05	-0.81	0.06	0.86	0.43	0.34	0.54		0.66	0.57	0.88	0.79	0.66	0.29	0.76	0.85	0.88	0.23	0.86	0.6	0.73	0.85
Total Liab	0.84	0.15	0.84	0.83	-0.45	-0.91	0.46	0.79	0.45	0.45	0.79	0.66		0.8	0.79	0.89	0.68	-0.15	0.85	0.72	0.81	0.84	0.7	0.89	0.97	0.78
Total Current Assets	0.94	0.0	0.76	0.94	-0.79	-0.85	0.8	0.78	0.37	0.21	1.0	0.57	0.8		0.72	0.93	0.7	-0.13	0.94	0.54	0.71	0.61	0.55	0.78	0.75	0.81
Net Receivables	0.91	-0.15	0.98	0.91	-0.16	-0.93	0.17	0.99	0.37	0.18	0.69	0.88	0.79	0.72		0.92	0.71	-0.12	0.91	0.94	0.98	0.36	0.94	0.76	0.87	0.98
Common Stock Shares Outstanding	0.99	-0.03	0.94	0.99	-0.52	-0.97	0.53	0.95	0.4	0.27	0.91	0.79	0.89	0.93	0.92		0.78	-0.11	0.99	0.79	0.92	0.55	0.8	0.86	0.88	0.95
Other Current Assets	0.77	0.27	0.8	0.77	-0.32	-0.79	0.33	0.76	0.25	0.45	0.68	0.66	0.68	0.7	0.71	0.78		-0.01	0.71	0.5	0.8	0.37	0.51	0.68	0.59	0.69
Common Stock	-0.13	0.17	-0.11	-0.13	0.08	0.12	-0.08	-0.12	0.09	0.13	-0.13	0.29	-0.15	-0.13	-0.12	-0.11	-0.01		-0.13	-0.11	-0.11	-0.14	-0.11	-0.19	-0.15	-0.13
Net Tangible Assets	0.99	-0.09	0.91	0.99	-0.55	-0.95	0.56	0.94	0.44	0.21	0.92	0.76	0.85	0.94	0.91	0.99	0.71	-0.13		0.79	0.88	0.52	0.8	0.8	0.86	0.96
Property Plant And Equipment Net	0.76	-0.15	0.91	0.75	0.01	-0.86	0.01	0.88	0.36	0.19	0.51	0.85	0.72	0.54	0.94	0.79	0.5	-0.11	0.79		0.91	0.29	1.0	0.7	0.84	0.91
Accounts Payable	0.89	0.0	1.0	0.89	-0.17	-0.96	0.19	0.97	0.35	0.32	0.69	0.88	0.81	0.71	0.98	0.92	0.8	-0.11	0.88	0.91		0.36	0.92	0.8	0.85	0.95
Non Current Liabilities Total	0.51	0.25	0.42	0.49	-0.53	-0.56	0.54	0.36	0.38	0.43	0.61	0.23	0.84	0.61	0.36	0.55	0.37	-0.14	0.52	0.29	0.36		0.25	0.68	0.76	0.35
Property Plant And Equipment Gross	0.77	-0.18	0.92	0.76	0.0	-0.86	0.01	0.89	0.34	0.16	0.52	0.86	0.7	0.55	0.94	0.8	0.51	-0.11	0.8	1.0	0.92	0.25		0.69	0.81	0.92
Short Long Term Debt	0.82	-0.06	0.83	0.81	-0.45	-0.91	0.47	0.76	0.05	0.21	0.77	0.6	0.89	0.78	0.76	0.86	0.68	-0.19	0.8	0.7	0.8	0.68	0.69		0.86	0.77
Short Term Debt	0.84	0.02	0.88	0.83	-0.32	-0.91	0.34	0.84	0.47	0.36	0.73	0.73	0.97	0.75	0.87	0.88	0.59	-0.15	0.86	0.84	0.85	0.76	0.81	0.86		0.85
Intangible Assets	0.95	-0.17	0.96	0.95	-0.31	-0.94	0.32	0.99	0.38	0.15	0.78	0.85	0.78	0.81	0.98	0.95	0.69	-0.13	0.96	0.91	0.95	0.35	0.92	0.77	0.85

Click cells to compare fundamentals

Zomedica Pharmaceuticals Account Relationship Matchups

Zomedica Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.2M	66.1M	280.4M	279.6M	253.2M	265.9M
Other Current Liab	1.0	1.2M	501.5K	265K	172K	163.4K
Total Current Liabilities	2.1M	2.0M	4.3M	7.8M	9.0M	9.5M
Total Stockholder Equity	2.1M	51.1M	270.9M	267.4M	240.0M	252.0M
Net Debt	(510.6K)	(60.1M)	(193.6M)	(25.7M)	(10.2M)	(10.7M)
Retained Earnings	(52.1M)	(69.0M)	(119.4M)	(136.4M)	(170.9M)	(162.4M)
Cash	510.6K	62.0M	195.0M	27.4M	13.0M	12.3M
Non Current Assets Total	2.4M	3.3M	80.0M	156.1M	153.3M	161.0M
Non Currrent Assets Other	(2.4M)	1M	659.1K	453K	1.1M	1.1M
Cash And Short Term Investments	510.6K	62.0M	195.0M	115.1M	90.5M	95.0M
Liabilities And Stockholders Equity	4.2M	66.1M	280.4M	279.6M	253.2M	265.9M
Other Stockholder Equity	3.6M	2.8M	9.3M	23.7M	29.9M	31.4M
Total Liab	2.1M	15.1M	9.5M	12.2M	13.2M	13.8M
Total Current Assets	1.8M	62.9M	200.4M	123.5M	99.9M	104.9M
Net Receivables	67.6K	146.2K	765.5K	1.9M	2.2M	2.3M
Common Stock Shares Outstanding	106.3M	364.4M	956.5M	979.9M	979.9M	1.0B
Other Current Assets	1.2M	727.8K	1.8M	3.8M	2.1M	1.4M
Accumulated Other Comprehensive Income	0.0	459.6K	1.7K	(843K)	48K	59.2K
Common Stock	38.6M	104.8M	381.0M	381.0M	342.9M	325.7M
Net Tangible Assets	(10.4M)	50.7M	194.1M	161.6M	185.9M	195.1M
Property Plant And Equipment Net	1.8M	1.9M	2.5M	9.2M	25.3M	26.6M
Accounts Payable	2.1M	1.2M	3.2M	6.7M	7.7M	8.1M
Common Stock Total Equity	38.6M	459.6	381.0M	381.0M	438.1M	460.0M
Retained Earnings Total Equity	(52.1M)	(69.0M)	(119.4M)	(136.4M)	(122.8M)	(116.6M)
Short Term Investments	570.0K	1.3M	1.0M	87.7M	77.5M	81.4M
Property Plant And Equipment Gross	2.4M	583.01	3.4M	10.4M	27.3M	28.7M
Intangible Assets	543.4K	376.6K	33.5M	41.8M	55.4M	58.1M
Property Plant Equipment	1.8M	583.0K	2.5M	6.8M	7.8M	8.2M
Cash And Equivalents	510.6K	62.0M	195.0M	27.4M	31.5M	46.1M
Capital Surpluse	3.6M	14.8M	9.3M	23.7M	27.2M	28.6M
Net Invested Capital	(9.9M)	51.6M	270.9M	267.4M	240.0M	130.1M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Zomedica Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Zomedica Pharmaceuticals' short interest history, or implied volatility extrapolated from Zomedica Pharmaceuticals options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
MSFT	Microsoft

When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:

How To Invest In Zomedica

Details

Is Zomedica Stock a good investment?

Details

What is Zomedica Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.

You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Zomedica Stock analysis

When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.

Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.04)

Revenue Per Share

0.026

Quarterly Revenue Growth

0.192

Return On Assets

(0.07)

Return On Equity

(0.14)

The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zomedica Capital Surpluse vs Net Receivables Analysis

Capital Surpluse vs Net Receivables

Capital Surpluse vs Net Receivables Correlation Analysis

Correlation Coefficient

Capital Surpluse

Net Receivables

Zomedica Pharmaceuticals fundamental ratios Correlations

Zomedica Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zomedica Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Zomedica Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Accounts Payable	+ 1.0	Total Current Liabilities
Total Current Assets	+ 1.0	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock Shares Outstanding	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Assets

Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Current Liabilities
Accounts Payable	- 0.96	Retained Earnings
Net Tangible Assets	- 0.95	Retained Earnings
Retained Earnings	- 0.95	Total Assets